NAP alpha-aminoisobutyric acid (IsoNAP)

Illana Gozes*, Yulie Schirer, Anat Idan-Feldman, Merav David, Sharon Furman-Assaf

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


We set out to identify NAP (davunetide) analogs, providing neuroprotection and reducing tau pathology, specifically addressing protection against protein misfolding. NAP (NAPVSIPQ, intranasal formulation AL-108) is a drug candidate that (1) had a statistically significant impact on two measures, namely digit span and delayed-match-to-sample, tests of verbal recall and visual working memory, respectively, in patient population of mild cognitive impairment [preceding Alzheimer's disease (AD)] and (2) protected functional activities of daily living in schizophrenia patients. Previous preclinical studies have shown that stabilization of NAP by replacement of all l-amino acids by d-amino acids resulted in an active peptide, d-NAP. Other NAP mimetics are now explored. A new NAP analog was designed that included replacement of the proline residues by alpha-aminoisobutyric acid to enhance β-sheet breaker characteristics, thereby reducing protein misfolding. Three lines of investigations were chosen: (1) protection against the AD-associated amyloid β (1-42), Aβ1-42, peptide toxicity in cell cultures; (2) inhibition of AD-associated tau aggregation in vitro; and (3) cognitive protection in a mouse model of deficiencies of the NAP parent protein, activity-dependent neuroprotective protein (ADNP), exhibiting tau pathology and neurodegeneration. NAP alpha-aminoisobutyric acid (IsoNAP) protected neurons against AD-associated Aβ1-42-toxicity, inhibited the aggregation of the tau-derived peptide VQIVYK (important for the aggregation of tau into paired helical filaments, which form the tangles found in AD and related disorders), and protected cognitive functions in a model of ADNP deficiency. With AD being the major tauopathy, novel NAP derivatives that reduce tauopathy and provide neuroprotection as well as cognitive protection are of scientific and clinical interest.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Molecular Neuroscience
Issue number1
StatePublished - Jan 2014


FundersFunder number
Adams family
Allon Therapeutics Inc.
Canadian Friends of Tel Aviv University
AAMN Foundation
Tel Aviv University


    • ADNP
    • ADNP-deficiency
    • NAP (davunetide)
    • NAP Alpha-Aminoisobutyric Acid (IsoNAP)
    • Neuroprotection
    • β-sheet breaker


    Dive into the research topics of 'NAP alpha-aminoisobutyric acid (IsoNAP)'. Together they form a unique fingerprint.

    Cite this